-
公开(公告)号:US20230086884A1
公开(公告)日:2023-03-23
申请号:US17822450
申请日:2022-08-26
发明人: Byoungmoon LEE , Hyunjoo LEE , Gyu Jin LEE , Su Bin CHOI , Sol PARK , Heejun KIM , Misong KIM , Young Ae YOON , Kwan Hoon HYUN , Tae Kyun KIM , Jae Young SIM , Marian C. BRYAN , Scott KUDUK , James Campbell ROBERTSON
IPC分类号: C07D401/14
摘要: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
-
公开(公告)号:US20230086795A1
公开(公告)日:2023-03-23
申请号:US17822438
申请日:2022-08-26
发明人: Hyunjoo LEE , Su Bin CHOI , Young Ae YOON , Kwan Hoon HYUN , Jae Young SIM , Marian C. BRYAN , Scott KUDUK , James Campbell Robertson , Jaekyoo LEE , Paresh Devidas SALGAONKAR , Byung-Chul SUH , Jong Sung KOH , So Young HWANG
IPC分类号: C07D401/14
摘要: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
-
公开(公告)号:USD965984S1
公开(公告)日:2022-10-11
申请号:US29751730
申请日:2020-09-23
申请人: YUHAN CORPORATION
设计人: Sung Jin Lee
-
公开(公告)号:US20220281861A1
公开(公告)日:2022-09-08
申请号:US17704718
申请日:2022-03-25
申请人: Yuhan Corporation
发明人: Sang-Ho Oh , Ja-Heouk Khoo , Jong-Chul Lim , Seong-Ran Lee , Hyun Ju , Woo-Seob Shin , Dae-Gyu Park , Su-Min Park , Yoon-Ah Hwang
IPC分类号: C07D413/14
摘要: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
-
公开(公告)号:US11434224B2
公开(公告)日:2022-09-06
申请号:US17056557
申请日:2019-05-16
申请人: YUHAN CORPORATION
发明人: Ja-Heouk Khoo , Doo-Byung Lee , Jun-Sup Lee , Hyun Ju , Woo-Seob Shin
IPC分类号: C07D403/04 , C07D239/47
摘要: Provided are a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist, crystalline forms of a hydrochloride of the diaminopyrimidine derivative, and processes for preparing the same.
-
6.
公开(公告)号:US11168073B2
公开(公告)日:2021-11-09
申请号:US16712660
申请日:2019-12-12
申请人: YUHAN CORPORATION
发明人: Tae Dong Han , Hee Jae Tak , Eun Kyung Kim , Eui Chul Lee , Sol Park , Hyok Jun Cho , Cheol Hee Lim , So Young Kim , Hyun Ho Choi , Da Na Jeong , Na Yeon Yang , Na Ry Ha
IPC分类号: C07D403/10 , C07D249/12 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/14
摘要: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
公开(公告)号:US11136364B2
公开(公告)日:2021-10-05
申请号:US15768865
申请日:2016-10-28
申请人: YUHAN CORPORATION
发明人: Jun Hwan Kim , Seyoung Lim , Minji Seo , Hyun Ho Choi , Dohoon Kim , Mi Kyeong Ju , Ju-Young Park , Seul Gi Kim , Sangmyoun Lim , Jong Gyun Kim , Su Youn Nam
IPC分类号: A61K38/18 , C07K14/50 , C07K14/575 , C07K14/605
摘要: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
-
公开(公告)号:US20210188936A1
公开(公告)日:2021-06-24
申请号:US16606279
申请日:2018-04-20
申请人: YUHAN CORPORATION
发明人: Byung Hyun CHOI , In Hwan LIM , Jun Young PARK , Jin Hyoung LEE , Ki Hong KIM , Hae Yong JO , Jun Hwan KIM , Moo Young SONG , Jong Gyun KIM
IPC分类号: C07K14/605 , C07K14/50 , C12P21/02
摘要: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
-
公开(公告)号:US20200325120A1
公开(公告)日:2020-10-15
申请号:US16096712
申请日:2017-04-26
申请人: YUHAN CORPORATION
发明人: Young-Hwan KIM , Tae-Dong HAN , Dong-Hoon KIM , Eun-Hye JUNG , Su-Bin CHOI , Eui-Chul LEE , Won-Ee CHONG , Jin-Hwi PARK , Jun-Chul PARK , Ho-Woong KANG , Ji-Yeong GAL , Chan-Sun PARK , Jong-Gyun KIM , Su-Youn NAM
IPC分类号: C07D403/14 , C07D239/91 , C07D217/24 , C07D403/12
摘要: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
-
10.
公开(公告)号:US20190142809A1
公开(公告)日:2019-05-16
申请号:US16315814
申请日:2017-07-06
申请人: Yuhan Corporation
发明人: Se-Woong Oh , Youn Hur , Jin-Hwi Park , Jae-Eun Joo , Ho-Woong Kang , Hyok-Jun Cho , Eui-Chul Lee , Chan-Sun Park , Dong-Hyun Kim , Jong-Gyun Kim , Su-Youn Nam
IPC分类号: A61K31/428 , A61P35/04
CPC分类号: A61K31/428 , A61K9/00 , A61K9/08 , A61K9/20 , A61P35/04 , C07D277/82
摘要: The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.
-
-
-
-
-
-
-
-
-